Back to JPMORGAN CHASE & CO JPMORGAN CHASE & CO

FDMTFDMT
7 quarters

Position history for JPMORGAN CHASE & COJPMORGAN CHASE & CO's holdings in 4D MOLECULAR THERAPEUTICS IN

JPMORGAN CHASE & CO holds 402,137 shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $5.2M as of 2026-Q2. The position was decreased (-3.3% shares). FDMT represents 0.0% of JPMORGAN CHASE & CO's portfolio.

Current Value

$5.2M

Current Shares

402,137

Total Value Change

+$611,739

Total Shares Change

-417,932

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
402,137
-3.3%
$5.2M0.0%$13.30
0
2026-Q1
Increased
415,655
+48.7%
$3.6M0.0%$8.46
37
2025-Q4
Decreased
279,505
-72.8%
$2.1M0.0%$7.58
0
2025-Q3
Increased
1M
+15.7%
$8.9M0.0%$8.35
32
2025-Q2
Increased
888,016
+0.1%
$3.3M0.0%$3.84
26
2025-Q1
Increased
886,705
+8.1%
$2.9M0.0%$3.63
28
2024-Q4
New
820,069
-
$4.6M0.0%$5.30
37

Other major holders of FDMT: VIKING GLOBAL INVESTORS LP, RA CAPITAL MANAGEMENT, L.P., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used